<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554863</url>
  </required_header>
  <id_info>
    <org_study_id>2017/01</org_study_id>
    <nct_id>NCT03554863</nct_id>
  </id_info>
  <brief_title>High Flow Oxygen in Patients Undergoing Surgery Under General Anesthesia</brief_title>
  <acronym>OPTIFLOW</acronym>
  <official_title>Does Optiflow Anesthesia Allow Anethesia Induction &quot;Without Hands&quot; ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CMC Ambroise Paré</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CMC Ambroise Paré</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preoxygenation remains an important determinant of morbidity and mortality in anesthesia
      despite advances in mask ventilation and difficult intubation management.

        1. The usual practice Preoxygenation prior to the injection of the anesthetic agents is the
           administration of pure oxygen to delay the occurrence of hypoxemia during the apnea
           phase and intubation maneuvers. It consists of applying a mask on the patient's face and
           allowing it to ventilate, ensuring a perfect seal of the device. The end of oxygen
           exhalation fraction is a good reflection of the alveolar oxygenation and a value of 95%
           corresponds to a &quot;total&quot; alveolar oxygenation. When this value is reached, the injection
           of the anesthetic agents (hypnotic, morphine and myorelaxant) leads to the loss of
           consciousness and apnea, which forces to continue the manual ventilation to the mask.
           Intubation is performed when the myorelaxation is complete.

        2. Anesthetic induction &quot;without the hands&quot; The Optiflow Anesthesia (Fisher and Paykel
           Healthcare, Auckland, New Zealand) device provides heated, Humidified High-Flow Nasal
           Oxygen.

      The hypothesis of this study is that Humidified High-Flow Nasal Oxygen, should allow
      anesthetic induction without having to impose the patient the establishment of a facial mask
      for several minutes before anesthetic induction and the doctor anesthetist assisted
      ventilation with the mask before intubation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Actual">February 14, 2019</completion_date>
  <primary_completion_date type="Actual">February 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recourse to another ventilation technique</measure>
    <time_frame>During the preoxygenation-induction-intubation period (30 min)</time_frame>
    <description>The preoxygenation-induction-intubation period is filmed (audio and video recording) and the use of mask ventilation will be confirmed a posteriori from the audio / video recording by two reviewers.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Facial mask</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Optiflow anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal High Flow Oxygen</intervention_name>
    <description>Nasal High Flow Oxygen using Optiflow device of Fisher and Paykel</description>
    <arm_group_label>Optiflow anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Facial Mask</intervention_name>
    <description>Preoxygenation with facial mask</description>
    <arm_group_label>Facial mask</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consent for participation

          -  Affiliation to the french social security system

          -  Patients benefit general anesthesia with oral intubation

        Exclusion Criteria:

          -  Pregnant or breastfeeding patients;

          -  Patients with difficulty of ventilation by Optiflow AnesthesiaTM (facial trauma);

          -  Patients under the protection of justice

          -  Patients with drained or undrained pneumothorax;

          -  Patients with a predicted difficulty of mask ventilation or intubation according to
             the clinical examination prior to inclusion (arne score ≥ 11) or when treating the
             patient in the operating room;

          -  Patients with coronary heart disease, heart failure or respiratory failure;

          -  Patients with intracranial pathology; patients with arterial oxygen saturation &lt;95% in
             the open air;

          -  Patients for whom the surgical procedure requires the installation of a double-lumen
             tube;

          -  Patients requiring rapid sequence induction; patients for whom the induction can not
             be carried out by the sequence sufentanil, propofol, rocuronium;

          -  Patients with sugammadex allergy;

          -  Patients placed under judicial protection

          -  Patients who have already been included in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FISCHLER Marc, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital FOCH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMC Ambroise Paré</name>
      <address>
        <city>Neuilly sur seine</city>
        <state>Ile De France</state>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <state>Ile De France</state>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthesia genral, Oxygen</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

